Shionogi to buy US-based IntraBio for $2bn to expand rare disease drugs

· Health · Japan · United States

Japan's Shionogi agreed to buy US-based IntraBio for $2bn to expand its rare disease drug business, Nikkei Asia reported. The acquisition adds a US rare-disease pipeline to Shionogi's portfolio as Japanese pharmaceutical firms seek growth abroad. The deal reflects broader consolidation in rare-disease treatments, where smaller biotechs with niche therapies attract large buyers.

Why it matters：The deal shows Japanese pharma's push into US rare-disease markets, a growing segment where acquisitions drive innovation.

Key points

  • Shionogi will buy IntraBio for $2bn.
  • The deal expands its rare disease drug business.
  • It adds a US pipeline to Shionogi's portfolio.

Sources (original reporting)

More stories from this day